FDA Expands Lilly's Olumiant Approval To Adolescents With Severe Alopecia Areata

Eli Lilly and Company (LLY) announced that the U.S. Food and Drug Administration approved Olumiant (baricitinib) for the treatment of severe alopecia areata in pediatric patients aged 12 years and older, extending the medicine's use beyond adults.